Holen Sie sich die Stockscreener-App
4.125
11.67%
-0.545
Handel nachbörslich:
4.26
0.135
+3.27%
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Aldeyra Awaits FDA Verdict On Dry Eye Drug Reproxalap - RTTNews
ALDX stock garners retail interest: Investors debate dry eye treatment approval amid long wait - MSN
ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait - Stocktwits
Aldeyra Therapeutics: Investor Attention Shifts to Upcoming Catalysts - AD HOC NEWS
Movement Recap: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
HC Wainwright Analysts Boost Earnings Estimates for ALDX - MarketBeat
HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
How volatile is Aldeyra Therapeutics Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - mfd.ru
EBITDA per share of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal - Stock Titan
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-02-28 16:42:08 - baoquankhu1.vn
Aldeyra Therapeutics, Inc. SEC 10-K Report - TradingView
Coya Therapeutics, Inc. (COYA) upgraded to buy: What does it mean for the stock? - MSN
Aldeyra Therapeutics, Inc.Common Stock (NQ: ALDX - The Chronicle-Journal
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Is Aldeyra Therapeutics (ALDX) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference - MarketBeat
Overview of FDA Regulatory Developments - Intellectia AI
Aldeyra Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Understanding Momentum Shifts in (ALDX) - Stock Traders Daily
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan
Perceptive fund discloses 7% Aldeyra (ALDX) ownership stake - Stock Titan
Biotech Stocks Facing FDA Decision In March 2026 - RTTNews
Does Aldeyra Therapeutics Inc. have a sustainable dividendJuly 2025 Reactions & Daily Profit Maximizing Tips - mfd.ru
Aldeyra's Dry Eye Therapy Faces FDA In MarchWill The Third Time Be A Charm? - RTTNews
Published on: 2026-02-12 20:14:42 - baoquankhu1.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily
Wall Street analysts predict a 65.75% upside in Aldeyra Therapeutics (ALDX): Here's what you should know - MSN
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know - Finviz
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Market Review: Does Aldeyra Therapeutics Inc have consistent dividend growthJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will BOOT benefit from green energy policies2025 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
ATA Creativity Global Among 3 Promising Penny Stocks - Yahoo Finance
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):